A new method to find the best treatment for pediatric cancer

A study led by researchers from the Nanobioengineering Group at IBEC, in collaboration with other research centers and hospitals in Barcelona, ​​uses a predictive biomarker to anticipate the success of drugs against rhabdomyosarcoma, which represents around 5 percent of childhood tumors . This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.

Read more…

Joan Montero, Senior researcher at IBEC and Clara Alcon, researcher at IBEC and first author of the article are featured in this article at “Investigación y Ciencia”.

You can read the full article here